Enzymotec Ltd. (NASDAQ:ENZY) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Tuesday.
According to Zacks, “Enzymotec, Ltd. provides specialty lipid-based products and solutions. The Company develops, manufactures and markets bio-functional lipid ingredients as well as final products. It serves pharmaceuticals and nutrition industries worldwide. Enzymotec, Ltd. is based in Migdal HaEmeq, Israel. “
Separately, Jefferies Group restated a “hold” rating on shares of Enzymotec in a report on Thursday, August 4th.
Enzymotec (NASDAQ:ENZY) opened at 7.09 on Tuesday. Enzymotec has a 1-year low of $6.60 and a 1-year high of $10.32. The stock has a market capitalization of $161.08 million, a price-to-earnings ratio of 37.32 and a beta of 1.27. The company has a 50-day moving average of $7.25 and a 200-day moving average of $8.11.
Enzymotec (NASDAQ:ENZY) last announced its quarterly earnings data on Tuesday, August 9th. The company reported $0.04 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.08 by $0.04. The business earned $15 million during the quarter, compared to analysts’ expectations of $14.90 million. Enzymotec had a return on equity of 3.12% and a net margin of 8.37%. Enzymotec’s revenue for the quarter was down 12.7% compared to the same quarter last year. During the same quarter last year, the company posted $0.11 EPS. Analysts anticipate that Enzymotec will post $0.27 earnings per share for the current fiscal year.
Several large investors have recently bought and sold shares of ENZY. Algert Global LLC boosted its stake in Enzymotec by 32.9% in the third quarter. Algert Global LLC now owns 50,566 shares of the company’s stock worth $354,000 after buying an additional 12,520 shares during the last quarter. Public Employees Retirement System of Ohio boosted its stake in Enzymotec by 48.6% in the second quarter. Public Employees Retirement System of Ohio now owns 35,187 shares of the company’s stock worth $294,000 after buying an additional 11,501 shares during the last quarter. Menta Capital LLC boosted its stake in Enzymotec by 12.4% in the second quarter. Menta Capital LLC now owns 48,488 shares of the company’s stock worth $405,000 after buying an additional 5,362 shares during the last quarter. Janus Capital Management LLC boosted its stake in Enzymotec by 79.3% in the second quarter. Janus Capital Management LLC now owns 248,485 shares of the company’s stock worth $2,077,000 after buying an additional 109,933 shares during the last quarter. Finally, Van ECK Associates Corp boosted its stake in Enzymotec by 5.9% in the second quarter. Van ECK Associates Corp now owns 12,659 shares of the company’s stock worth $106,000 after buying an additional 706 shares during the last quarter. Hedge funds and other institutional investors own 36.20% of the company’s stock.
Enzymotec Company Profile
Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.